Finanzen von iBio Inc (IBIO)IBIOiBio Inc

iBio Inc (IBIO) generates its revenue primarily from iBio CDMO, which accounts for 100.0% of total sales, equivalent to $61.00K. Understanding this concentration is critical for investors evaluating how IBIO navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, iBio Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -30138.00%, while the net margin is -33044.00%. These profitability ratios, combined with a Return on Equity (ROE) of -65.70%, provide a clear picture of how effectively IBIO converts its operational activities into shareholder value.

In the context of the broader market, IBIO competes directly with industry leaders such as ZSTK and UPXI. With a market capitalization of $47.23M, it holds a significant position in the sector. When comparing efficiency, IBIO's gross margin of 100.00% stands against ZSTK's 11.85% and UPXI's 94.72%. Such benchmarking helps identify whether iBio Inc is trading at a premium or discount relative to its financial performance.

iBio has a gross margin of 100% across recent quarters, indicating strong potential profitability if revenue can be stabilized. However, the company has reported increasing net losses, with Q4 2026 projected at -10,601,000 USD, raising concerns about its financial health.